Incretin and metabolic
Mazdutide
Lyophilized Mazdutide, unreconstituted. It is discussed in metabolic research as a glucagon and GLP-1 receptor agonist peptide.
Also searched as: MAZ
5 mg
€59.99
- Amount
- 5 mg, 10 mg, 20 mg
- Storage
- −20 °C · dry · dark
- COA
- Supplier certificate pending
About this material
Mazdutide is supplied by Rierink Compounds as a laboratory research material. Made in Europe. It is discussed in metabolic research as a glucagon and GLP-1 receptor agonist peptide. It sits with the peptides studied in laboratory research on incretin and metabolic signaling. The material is a lyophilized powder and is supplied unreconstituted. The companion reagent listed for it is BAC water. Store at −20 °C, dry and protected from light. For laboratory research use only. Not a medicine. Not for human or veterinary use. Rierink does not publish reconstitution volumes, dosing, or administration guidance.
Research context
Mazdutide. It is discussed in metabolic research as a glucagon and GLP-1 receptor agonist peptide.
Published studies describe a research material and a study design. They are not a protocol for this vial, not a dose, and not a permission for human or veterinary use.
Recommended reagent
This is the laboratory reagent listed with this lyophilized material.
Certificates
These certificates come from our supplier and relate to the supplier's batches. They are not Rierink's own independent tests of the exact vial you receive. Every Rierink vial carries our own internal lot number, and independent testing of our own lots is underway; results will be published per lot. We welcome independent testing: any customer or lab is free to test our products, and we're happy to share results sent to us.
Supplier certificate pending
Research briefings
- Favorable and unfavorable findings on TirzepatideClinical trials and meta-analyses of tirzepatide report substantial mean weight loss (15–21%), glycemic improvements, cardiometabolic benefits, heart failure event reduction, and superior weight loss versus semaglutide. These are accompanie
- Favorable and unfavorable findings on RetatrutideClinical trials of retatrutide (LY3437943), a GIP/GLP-1/glucagon triple receptor agonist, report substantial mean weight loss (18-25% at 80 weeks in phase 3 TRIUMPH studies), glycemic improvements, cardiometabolic benefits, and gains in knee osteoarthritis pain and obstructive sleep apnea. However, dose-dependent gastrointestinal adverse events, dysesthesia, increased heart rate, and higher discontinuation rates are consistently reported alongside inconclusive cardiovascular outcomes and data gaps on long-term safety.
- Published Reports on TirzepatideIndexed preclinical and clinical papers describe tirzepatide as a dual GIP/GLP-1 receptor agonist studied for glycemic and weight-related readouts, distinct from the single-incretin, GHRH-analog, and mitochondrial-peptide literature already
Trustpilot
A small laboratory is built one honest sentence at a time.
We're new on Trustpilot and don't have any reviews yet. Be one of the first to share your experience.
We are still the company that picks up the phone. The next researcher finds us because someone wrote down what actually happened: the lot that matched the label, the parcel that arrived late, the reply that took a day too long. That public record is how a young lab earns a name.
Write the first review